In the absence of targetable mutations and in selected ESR1 wild-type patients, particularly those with asymptomatic disease progression and low tumor burden, continuing CDK4/6 inhibitors beyond progression may represent a more viable approach compared to fulvestrant monotherapy in the second-line setting. The gene discussed is ESR1; the disease is neoplasm.